Drug Profile
Orismilast - UNION Therapeutics
Alternative Names: IBI-353; LEO32731; LP-0058; UNI-50001; UNI-50002Latest Information Update: 21 Mar 2024
Price :
$50
*
At a glance
- Originator LEO Pharma
- Developer Innovent Biologics; LEO Pharma; UNION Therapeutics
- Class Anti-inflammatories; Antipsoriatics; Benzodioxoles; Chlorinated hydrocarbons; Fluorinated hydrocarbons; Pyridines; Skin disorder therapies; Small molecules; Spiro compounds
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Atopic dermatitis; Hidradenitis suppurativa; Plaque psoriasis; Ulcerative colitis
Most Recent Events
- 15 Mar 2024 Adverse events and efficacy data from a phase II OSIRIS trial for Hidradenitis suppurativa released by UNION Therapeutics (PO)
- 15 Mar 2024 UNION Therapeutics completes enrolment in phase II OSIRIS trial for Hidradenitis suppurativa in Denmark (PO)
- 01 Jan 2024 Phase-II clinical trials in Ulcerative colitis in Denmark (PO)